Media, scientific publications and conference abstracts

Read about NEO and the science behind our technology

  • Liquid biopsies transform lung cancer therapy. 2016. MedNous. April, page 13.
  • Neue Technologie zur Tumordiagnostik. 2016. ÄrzteZeitung. No. 37-65D.
  • Neue Technologie für die molekulare Tumordiagnostik: Nachweis aller relevanten Genveränderungen an einer Tumorprobe. 2015. Der Onkologe. Volume 21, issue 10.
  • Molekulare Diagnostik beim nicht-kleinzelligen Bronchialkarzinom: Neue Technologie zum raschen Nachweis aller therapierelevanten Genanomalien. 2015. Der Pneumologe. Volume 12, issue 6.
  • Majewska H, Gorczyński A, Czapiewski P, Menon R et al. ALK alterations in salivary gland carcinomas. 2020. Virchows Arch. Nov 25.

  • Schatz S, Falk M, Jóri B et al. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. 2020. Cancers. 12(6), 1685.

  • Gautschi O, Bubendorf L, Leyvraz S, Menon R, Diebold J. Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.2020. J Thorac Oncol. 15(7)e108-e110.

  • Giannini R, Moretti S, Colella R, Panfili M et al. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like. 2019. J Clin Endocrinol Metab. Aug 1;104(8):3557-3575.

  • Jaekel N, Siebolts U, Menon R, Bertrand M et al. Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO). 2019. Blood. 134 (Supplement_1): 1420.
  • Gautschi O, Menon R, Bertrand M, Murer C, Diebold J. Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma. 2020. J Thorac Oncol. Jan;15(1):e13-e15.
  • Michels S, Massutí B, Schildhaus HU, Menon R et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. 2019. J Thorac Oncol. 14(7):1266-1276.
  • Heuckmann JM et al. Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. 2017. J Thorac Oncol 12(3):e22-e24.
  • Scheffler M et al. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. 2015. J Thorac Oncol. 10:e40-3.
  • Kloth M et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. 2015. Gut.
  • Mazières J et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. 2015. J Clin Oncol. 33:992-9.
  • Heuckmann JM et al. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibitor in lung cancer. 2012. J Clin Oncol. 30:3417-20.
  • Peifer M et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 2012. Nat Genet. 44:1104-10.
  • Chmielecki J et al. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. 2012. Genes Chromosomes Cancer. 51:54-65.
  • Weiss J et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010. Sci Transl Med. 2:62-93.
  • Chmielecki J et al. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. 2010. Nucleic Acids Res. 38:6958-96.
  • Thomas RK et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006. Nat Med. 12:852-5.



  • Jóri B et al. Hybrid Capture-Based Assays in Primary Diagnostics of NSCLC Patients – Results from the NEOlung Study. ESMO 2020. Abstract 2005/1246P.
    Abstract  Poster
  • Mueller J et al. Comparison of genomic alterations derived from matched tumor tissue and liquid biopsy. WCLC 2016. Abstract P2.03b-081.
    Abstract  Poster
  • Wiest G et al. Detection of an EGFR Kinase Domain Duplication in a Lung Adenocarcinoma Patient by Liquid Biopsy using Hybrid Capture-based Next Generation Sequencing. DGHO 2016. Abstract 291.
    Abstract  Poster
  • Mueller J et al. Hybrid-capture based sequencing assays to detect novel alterations in BRAF from tissue and liquid biopsies. ESMO 2016. Abstract 2761.
    Abstract  Poster
  • Heukamp L et al. Detection of actionable genome alterations using hybrid capture based next generation sequencing technology- NEOplus and NEOliquid. ASCO 2016. Abstract e23181.
  • Menon R et al. Identification of Therapeutically Targetable Genomic Alterations in a cohort of patients with CUP using a Hybrid-Capture based Next Generation Sequencing Assay. AACR 2016. Abstract 152.
    Abstract  Poster
  • Menon R et al. NEOliquid: Detection of KIF5B-RET fusions in liquid biopsy samples. ELCC 2016. Abstract 431.
    Abstract  Poster
  • Menon R et al. Discovery of a Novel EGFR Resistance Mutation by Capture Based NGS Following AZD9291 Treatment. Oncol Res Treat 2016;39(suppl 1):120.
    Abstract  Poster
  • Dziadziuszko R et al. Discrepancies Between ALK FISH and Capture Based NEOplus Diagnostics. WCLC 2015. Abstract 2748.
    Abstract  Poster
  • Menon R et al. Successful AZD9291 Therapy Based on NEOliquid Detection of Circulating T790M in a Liquid Biopsy Sample. 2015. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Abstract B135.
    Abstract  Poster